Monte Rosa Therapeutics Financial Statements
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Monte Rosa Therapeutics revenue and earnings
In fiscal 2025, Monte Rosa Therapeutics generated $123.7 million in revenue, up 63.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Monte Rosa Therapeutics reported a net loss of $38.6 million, compared with a loss of $72.7 million a year earlier. Operating margin was -43.8%.
Diluted earnings per share came in at -$0.46.
Summary generated from market data by MetaCap's automated system. Methodology
Monte Rosa Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 123.67M | 75.62M | 0 | — | — | — |
| Revenue growth (YoY) | +63.54% | — | — | — | — | — |
| Operating Expenses | 177.88M | 156.73M | 143.31M | 112.38M | 72.88M | 28.01M |
| Research & Development | 141.50M | 121.56M | 111.27M | 85.06M | 57.16M | 24.00M |
| Operating Income | -54.21M | -81.11M | -143.31M | -112.38M | -72.88M | -28.01M |
| Other Income (Expense) | 14.48M | 10.98M | 8.30M | 3.88M | -1.08M | -7.87M |
| Pretax Income | -39.72M | -70.13M | -135.01M | -108.50M | -9.88M | -10.11M |
| Income Tax | -1.10M | 2.57M | 338.00K | 0 | — | — |
| Net Income | -38.60M | -72.70M | -135.35M | -108.50M | -73.96M | -35.88M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -0.46 | -0.98 | -2.63 | -2.30 | -2.96 | -23.65 |
| EPS (Diluted) | -0.46 | -0.98 | -2.63 | -2.30 | -2.96 | -23.65 |
| Shares Outstanding (Basic) | 83.07M | 73.91M | 51.40M | 47.23M | 25.00M | 1.52M |
| Shares Outstanding (Diluted) | 83.07M | 73.91M | 51.40M | 47.23M | 25.00M | 1.52M |
| EBITDA | -45.85M | -72.99M | -137.09M | -108.64M | -70.75M | -27.47M |
| Operating Margin | -43.83% | -107.26% | — | — | — | — |
| Net Margin | -31.21% | -96.14% | — | — | — | — |
This table shows 6 annual periods of Monte Rosa Therapeutics's income statement, from FY 2025 back to FY 2020, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow GLUE's reporting calendar. What is a income statement?